Insider Analysis From Kantar Health China On The Implications Of China’s New EDL For Pharma
This article was originally published in PharmAsia News
Executive Summary
China’s Ministry of Health issued the new Essential Drug List on March 15, which significantly broadens coverage and now includes many best-selling products from multinational companies. This update will have serious implications for multinational pharmaceutical corporations operating in China.